Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
12–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult aged ≥ 18 years (at all sites) or adolescent aged ≥ 12 and weighing ≥ 35 kg (at sites in North America and Dominican Republic)
Currently receiving a stable failing ARV regimen for \> 8 weeks
Have HIV-1 RNA ≥ 400 copies/mL at screening
Have multidrug resistance (resistance to ≥2 agents from ≥3 of the 4 main classes of ARV)
Have no more than 2 fully active ARV remaining from the 4 main classes that can be effectively combined to form a viable regimen
Able and willing to receive an OBR together with lenacapavir
No Hepatitis C virus (HCV) ongoing infection
Clareo Health | Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance
